Tamoxifen-induced hepatotoxicity.
Ahbeddou N, Belbaraka R, Fetohi M, Errihani H.
Indian J Cancer. 2011 Jul-Sep;48(3):385. doi: 10.4103/0019-509X.84935.
Chemotherapy-associated steatohepatitis.
Meunier L, Larrey D.
Ann Hepatol. 2020 Nov-Dec;19(6):597-601. doi: 10.1016/j.aohep.2019.11.012. Epub 2020 Jan 30.
Drug-induced liver injury secondary to tamoxifen.
Subhaharan D, Murphy G, Commins N, Azer M.
BMJ Case Rep. 2024 Jun 5;17(6):e260098. doi: 10.1136/bcr-2024-260098.
Tamoxifen-induced non-alcoholic steatohepatitis: where are we now and where are we going?
Osman KA, Osman MM, Ahmed MH.
Expert Opin Drug Saf. 2007 Jan;6(1):1-4. doi: 10.1517/14740338.6.1.1.
Drug-Induced Fatty Liver Disease (DIFLD): A Comprehensive Analysis of Clinical, Biochemical, and Histopathological Data for Mechanisms Identification and Consistency with Current Adverse Outcome Pathways.
López-Pascual E, Rienda I, Perez-Rojas J, Rapisarda A, Garcia-Llorens G, Jover R, Castell JV.
Int J Mol Sci. 2024 May 10;25(10):5203. doi: 10.3390/ijms25105203.
Tamoxifen-induced steatohepatitis.
Pratt DS, Knox TA, Erban J.
Ann Intern Med. 1995 Aug 1;123(3):236. doi: 10.7326/0003-4819-123-3-199508010-00018.
Tamoxifen-induced steatohepatitis.
Van Hoof M, Rahier J, Horsmans Y.
Ann Intern Med. 1996 May 1;124(9):855-6. doi: 10.7326/0003-4819-124-9-199605010-00015.
Tamoxifen in advanced breast cancer.
Mouridsen H, Palshof T, Patterson J, Battersby L.
Cancer Treat Rev. 1978 Sep;5(3):131-41. doi: 10.1016/s0305-7372(78)80017-6.
Mitochondria: the gateway for tamoxifen-induced liver injury.
Ribeiro MP, Santos AE, Custódio JB.
Toxicology. 2014 Sep 2;323:10-8. doi: 10.1016/j.tox.2014.05.009. Epub 2014 Jun 2.
Tamoxifen-induced hepatotoxicity via lipid accumulation and inflammation in zebrafish.
Yu Q, Huo J, Zhang Y, Liu K, Cai Y, Xiang T, Jiang Z, Zhang L.
Chemosphere. 2020 Jan;239:124705. doi: 10.1016/j.chemosphere.2019.124705. Epub 2019 Aug 29.
